Meeting
2013 ASCO Annual Meeting
Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for muscle-invasive bladder cancer (MIBC): Japan Clinical Oncology Group study, JCOG0209.
Authors
Hiroshi Kitamura
School of Medicine, Sapporo Medical University, Sapporo, Japan
Hiroshi Kitamura , Taiji Tsukamoto , Naoya Masumori , Taro Shibata , Futoshi Kunieda , Hiroyuki Fujimoto , Yoshihiko Hirao , Yasuo Kitamura , Yoshihiko Tomita , Kenichi Tobisu , Masashi Niwakawa , Seiji Naito , Masatoshi Eto , Yoshiyuki Kakehi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Bladder Cancer
Clinical Trial Registration Number
C000000093
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4526)
DOI
10.1200/jco.2013.31.15_suppl.4526
Abstract #
4526
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.
First Author: Srikala S. Sridhar
Poster
2019 ASCO Annual Meeting
Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).
First Author: Benjamin Miron
Poster
2019 Genitourinary Cancers Symposium
Comparing clinical outcomes between patients with urothelial carcinoma who treated neoadjuvant chemotherapy by gemcitabine-cisplatin and dose-dense MVAC.
First Author: Yongjune Lee
Poster
2018 Genitourinary Cancers Symposium
Randomized phase III study of gemcitabine and cisplatin (GC) versus dose dense methotrexate, vinblastine, doxorubicin and cisplatin (DD-MVAC) in the perioperative setting for patients with locally advanced transitional cell cancer of the bladder: The French GETUG/AFU V05 VESPER trial.
First Author: Christian Pfister